skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Letter: Why does milnacipran produce so few discontinuation syndromes following abrupt withdrawal?

(2257) Views  (438) Full article downloads

Authors: Fumihiko Okada

Published Date May 2007 Volume 2007:3(1) Pages 181 - 182
DOI: http://dx.doi.org/10.2147/NDT.S

Fumihiko Okada

Sapporo Mental Clinic, Higashi-ku, Sapporo, Japan

Abstract: Several selective serotonin reuptake inhibitors (SSRI), especially paroxetine, have been reported to produce a number of post-treatment emergent adverse events following abrupt withdrawal (Coupland et al 1996; Haddad 1997). More recently a SSRI-induced neonatal withdrawal syndrome has been described (Sanz et al 2005) in infants born of mothers treated with SSRI during pregnancy. In both of these situations, paroxetine has been associated with the greatest incidence (Warner et al 2006; Sanz et al 2005). Other SSRIs and the selective serotonin and noradrenaline reuptake inhibitor (SNRI) venlafaxine can, however also cause a withdrawal syndrome in patients (Trenque et al 2002). In contrast, milnacipran, another SNRI, has been reported to present a lower risk of withdrawal-induced adverse events (Vandel et al 2004). Furthermore the spectrum of the symptoms was different from that produced by paroxetine.








Readers of this article also read:

Wine consumers’ environmental knowledge and attitudes: Influence on willingness to purchase
Enhanced endothelial cell functions on rosette nanotube-coated titanium vascular stents
Fosphenytoin for the treatment of status epilepticus: an evidence-based assessment of its clinical and economic outcomes
Assessment of musculoskeletal system in women with jumping mechanography
Mitigating micro- and macro-vascular complications of diabetes beginning in adolescence
Computational methods for the identification of microRNA targets
Reference values of hematological indices of infants, children, and adolescents in Port Harcourt, Nigeria
Sensitization with atypical mycobacteria is a potent risk factor for cross-reaction with the delayed type hypersensitivity assay in mice
Current and emerging treatment strategies for the treatment of actinic keratosis
Nanostructured delivery system for zinc phthalocyanine: preparation, characterization, and phototoxicity study against human lung adenocarcinoma A549 cells